Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
2(22%)
Results Posted
50%(2 trials)

Phase Distribution

Ph not_applicable
1
11%
Ph phase_3
2
22%
Ph early_phase_1
1
11%
Ph phase_2
5
56%

Phase Distribution

1

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
2(22.2%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(4)
Other(2)

Detailed Status

Completed4
unknown2
Enrolling by invitation1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 25 (55.6%)
Phase 32 (22.2%)
N/A1 (11.1%)

Trials by Status

unknown222%
enrolling_by_invitation111%
recruiting111%
active_not_recruiting111%
completed444%

Recent Activity

2 active trials
Showing 5 of 9
active_not_recruitingphase_3

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

NCT03519971
enrolling_by_invitationnot_applicable

Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT06715501
recruitingphase_3

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

NCT04460352
completedphase_2

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

NCT01969578
completedearly_phase_1

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

NCT06062602
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03519971Phase 3

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Active Not Recruiting
NCT06715501Not Applicable

Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Enrolling By Invitation
NCT04460352Phase 3

Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

Recruiting
NCT01969578Phase 2

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Completed
NCT06062602Early Phase 1

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Completed
NCT04982549Phase 2

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unknown
NCT02924909Phase 2

Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer

Unknown
NCT00873119Phase 2

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Completed
NCT00919880Phase 2

Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9